Arcturus Therapeutics Holdings Inc. (ARCT)
| Market Cap | 1.16B |
| Revenue (ttm) | 8.70M |
| Net Income (ttm) | -163.04M |
| Shares Out | 26.32M |
| EPS (ttm) | -6.49 |
| PE Ratio | n/a |
| Forward PE | 1.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98,066 |
| Open | 43.71 |
| Previous Close | 43.81 |
| Day's Range | 43.45 - 45.00 |
| 52-Week Range | 24.87 - 129.71 |
| Beta | 2.81 |
| Analysts | Buy |
| Price Target | 78.46 (+76.3%) |
| Est. Earnings Date | Nov 8, 2021 |
About ARCT
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issue...
Financial Performance
In 2020, ARCT's revenue was $9.54 million, a decrease of -54.12% compared to the previous year's $20.79 million. Losses were -$72.15 million, 177.6% more than in 2019.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is 78.46, which is an increase of 76.33% from the latest price.
News
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will Skyrocket
These growth stocks could rebound in a big way.
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
The company disappointed last year, but things may be turning around.
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154,...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on th...
After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?
Three healthcare giants are vying for the prize.
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-1...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARC...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine
7 Busted Biotech Stocks Due for a Rebound
Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More
With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.
Arcturus Therapeutics Stock Jumps On mRNA COVID-19 Vaccine Update
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported a Q2 EPS loss of $(2.07), beating the consensus of $(2.14). The cash balance totaled $433.6 million.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -4.02% and -27.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Prog...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
Earnings Previews: AMC, New Oriental Education and 3 Cathie Wood Picks
More than a third of earnings reports released Friday morning failed to meet consensus estimates for profits, revenues or both.
Why Arcturus Therapeutics Stock Is Soaring Today
The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country.
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on th...
Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam
The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19 vaccine candidate targeting variants of con...
Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its investigational COVID-19 vaccines for sale and use within Viet...
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investi...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornit...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for OTC Deficiency
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
SAN DIEGO, Calif.--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences